Overview

The Solid Tumor 410 gene panel profiles a broad constellation of tumor-associated genes to surface actionable alterations across many cancer types. This article centers on the sequencing mechanism that lets a single assay support diverse solid tumor indications, performed by GIVE LIFE TIME International for oncology networks. Wide content reduces the need to guess which pathway drives a given metastasis.

How It Works

Hybridization-based capture enriches 410 gene regions from the tumor sample before sequencing at high depth on an Illumina platform. The resulting data pass through variant calling and annotation steps that flag clinically relevant mutations, fusions, and microsatellite instability. A second review layer confirms low-frequency calls before the report is finalized.

Indications

Medical oncologists order this panel for metastatic solid tumors lacking a clear driver, for therapy selection after progression, and for trial matching. It suits colorectal, breast, prostate, and other carcinomas needing wide genomic coverage. The breadth also helps when histology alone gives little clue about the driving alteration.

Specimen & Processing

Formalin-fixed paraffin-embedded tissue is preferred, with at least 10 unstained sections or isolated nucleic acid meeting the minimum input. Circulating tumor DNA from plasma is accepted when a tissue biopsy cannot be obtained. Nucleic acid quality is measured before capture to protect assay performance. Sample identity is confirmed at every handoff, and residual material from the mechanism-focused workflow is retained for optional confirmatory re-analysis.

Storage & Sourcing

Reports are released as a secure PDF through the portal within ten to twelve working days, with raw BAM and VCF files available on request. GIVE LIFE TIME International provides B2B clients with batch pricing, white-label reporting, and cold-chain logistics for cross-border samples. Client portals return multi-language reports for the Solid program and support bulk export to hospital information systems.

FAQ

Q: What tumor types are covered by the 410 panel? A: All common solid malignancies are supported, with gene content chosen to span colorectal, breast, prostate, pancreatic, and other carcinomas. Rare tumors are covered through the shared core gene set.

Q: What sequencing depth is used for the assay? A: Tumor regions are sequenced to a depth that resolves low-frequency variants while keeping turnaround practical for clinical decision making. Depth is documented in the report appendix.

Q: How long until the report is ready? A: Most cases return within ten to twelve working days from sample receipt, including bioinformatics review. Complex fusions may add a short confirmation step.

Q: Can the panel detect gene fusions and copy changes? A: Yes, the capture design and analysis report both structural fusions and copy number alterations alongside point mutations. Transcript fusion calls use the RNA input when supplied.